MX2019002518A - Metodos y vectores para el tratamiento de trastornos del snc. - Google Patents
Metodos y vectores para el tratamiento de trastornos del snc.Info
- Publication number
- MX2019002518A MX2019002518A MX2019002518A MX2019002518A MX2019002518A MX 2019002518 A MX2019002518 A MX 2019002518A MX 2019002518 A MX2019002518 A MX 2019002518A MX 2019002518 A MX2019002518 A MX 2019002518A MX 2019002518 A MX2019002518 A MX 2019002518A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- vectors
- cns disorders
- treating cns
- mammalian
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 210000000056 organ Anatomy 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383274P | 2016-09-02 | 2016-09-02 | |
| PCT/US2017/049959 WO2018045347A1 (en) | 2016-09-02 | 2017-09-01 | Methods and vectors for treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002518A true MX2019002518A (es) | 2019-07-18 |
Family
ID=61309371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002518A MX2019002518A (es) | 2016-09-02 | 2017-09-01 | Metodos y vectores para el tratamiento de trastornos del snc. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190192693A1 (enExample) |
| EP (1) | EP3506930A4 (enExample) |
| JP (2) | JP7610923B2 (enExample) |
| CN (1) | CN110121356A (enExample) |
| AU (2) | AU2017318717B2 (enExample) |
| BR (1) | BR112019004353A2 (enExample) |
| CA (1) | CA3035628A1 (enExample) |
| MX (1) | MX2019002518A (enExample) |
| WO (1) | WO2018045347A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| CA3069880A1 (en) * | 2017-07-17 | 2019-01-24 | Spark Therapeutics, Inc. | Apheresis methods and uses |
| IL313246B2 (en) | 2018-06-28 | 2025-10-01 | Univ North Carolina Chapel Hill | Optimal cln5 expression genes and cassettes and their use |
| AU2019346447A1 (en) | 2018-09-26 | 2021-04-29 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| KR20210092755A (ko) * | 2018-11-14 | 2021-07-26 | 리젠엑스바이오 인크. | 신경원성 세로이드 리포푸신증에 대한 유전자 요법 |
| KR20210096168A (ko) * | 2018-11-28 | 2021-08-04 | 프리베일 테라퓨틱스, 인크. | 신경퇴행성 질환을 위한 유전자 요법 |
| US12416017B2 (en) | 2019-02-22 | 2025-09-16 | The Trustees Of The University Of Pennsylvania | Recombinant adeno-associated virus for treatment of GRN-associated adult-onset neurodegeneration |
| WO2021061909A1 (en) * | 2019-09-24 | 2021-04-01 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Method of targeting neuronal apoe to treat a neurocognitive disorder |
| CN114761569A (zh) * | 2019-10-16 | 2022-07-15 | 康奈尔大学 | 阿尔茨海默氏病的基因疗法 |
| AU2021351720A1 (en) * | 2020-10-01 | 2023-05-11 | Sangamo Therapeutics, Inc. | Methods of detecting anti-aav antibodies |
| CN112852881B (zh) * | 2021-02-09 | 2023-08-15 | 南京贝思奥生物科技有限公司 | 利用细胞穿膜肽增强腺相关病毒在中枢神经系统转导效率的方法 |
| TW202426479A (zh) * | 2022-10-10 | 2024-07-01 | 美商星火治療公司 | Apoe基因療法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135339B2 (en) * | 2003-11-20 | 2006-11-14 | University Of Iowa Research Foundation | Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) |
| WO2012057363A1 (ja) * | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
| ES2786078T3 (es) * | 2012-05-18 | 2020-10-08 | Univ Iowa Res Found | Métodos y composiciones para tratar depósitos amiloides |
| DK3024497T3 (da) * | 2013-07-26 | 2021-04-12 | Univ Iowa Res Found | Fremgangsmåder og præparater til behandling af hjernesygdomme |
| AU2014352944A1 (en) * | 2013-11-20 | 2016-06-16 | The General Hospital Corporation | Methods and compositions for treating amyloid deposits |
| SG11201706755SA (en) * | 2015-02-20 | 2017-09-28 | Univ Iowa Res Found | Methods and compositions for treating genetic eye diseases |
-
2017
- 2017-09-01 CA CA3035628A patent/CA3035628A1/en active Pending
- 2017-09-01 US US16/329,697 patent/US20190192693A1/en not_active Abandoned
- 2017-09-01 MX MX2019002518A patent/MX2019002518A/es unknown
- 2017-09-01 CN CN201780067677.9A patent/CN110121356A/zh active Pending
- 2017-09-01 BR BR112019004353A patent/BR112019004353A2/pt unknown
- 2017-09-01 AU AU2017318717A patent/AU2017318717B2/en active Active
- 2017-09-01 EP EP17847658.6A patent/EP3506930A4/en active Pending
- 2017-09-01 WO PCT/US2017/049959 patent/WO2018045347A1/en not_active Ceased
- 2017-09-01 JP JP2019512292A patent/JP7610923B2/ja active Active
-
2022
- 2022-01-11 JP JP2022002163A patent/JP2022050574A/ja active Pending
-
2024
- 2024-10-06 AU AU2024227138A patent/AU2024227138A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3506930A1 (en) | 2019-07-10 |
| BR112019004353A2 (pt) | 2019-05-28 |
| AU2017318717B2 (en) | 2024-10-24 |
| JP7610923B2 (ja) | 2025-01-09 |
| CA3035628A1 (en) | 2018-03-08 |
| AU2017318717A1 (en) | 2019-03-21 |
| US20190192693A1 (en) | 2019-06-27 |
| JP2019529385A (ja) | 2019-10-17 |
| JP2022050574A (ja) | 2022-03-30 |
| EP3506930A4 (en) | 2020-09-23 |
| AU2024227138A1 (en) | 2024-10-31 |
| CN110121356A (zh) | 2019-08-13 |
| WO2018045347A1 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002518A (es) | Metodos y vectores para el tratamiento de trastornos del snc. | |
| PH12018500401B1 (en) | Antibodies specific for tgf-beta | |
| EA201891152A1 (ru) | Экстрацеллюлярные везикулы нервных клеток | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EP4269566A3 (en) | Genetic markers for engraftment of human cardiac ventricular progenitor cells | |
| EA201691368A1 (ru) | ПИРРОЛИДИНИЛСУЛЬФОНОВЫЕ МОДУЛЯТОРЫ RORγ | |
| CR20140267A (es) | Metodos para tratar transtornos relacionados con mutante viii de eliminacion de factor de crecimiento epidérmico | |
| PH12014502449A1 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| CY1119420T1 (el) | Νεες θεραπευτικες προσεγγισεις για θεραπεια ασθενειας parkinson | |
| MX352772B (es) | Composición y método para el diagnóstico y tratamiento de enfermedades asociadas con la degeneración de neuritas. | |
| EA201490697A1 (ru) | Белки с двойной функцией для лечения метаболических расстройств | |
| MX2020011415A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| MY189857A (en) | Methods of selecting t cell line and donor thereof for adoptive cellular therapy | |
| DOP2014000096A (es) | Moduladores del receptor mas acoplado a la proteína g y el tratamiento de trastornos relacionados con el mismo | |
| MX2016008449A (es) | Inhibidores de serina/treonina cinasa. | |
| MY179105A (en) | Methods of treating alzheimer's disease | |
| PH12017500032B1 (en) | Improved aã protofibril binding antibodies | |
| MX2019005266A (es) | Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas. | |
| MX2016009306A (es) | Reequilibrado inmunologico epicutaneo. | |
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| MX2025001445A (es) | Anticuerpos monoclonales anti-trkb y metodos de uso | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| MX382488B (es) | Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas. | |
| WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
| WO2013052158A3 (en) | Targeted nanovectors and their use for treatment of brain tumors |